Drug Database
Back to search

Czechia· CZ-0222910

MYLOTARG

A gemtuzumab ozogamicin product containing gemtuzumab ozogamicin, registered in Czechia by Pfizer Europe MA EEIG, Bruxelles. The same ATC class is registered in 12 of our 19 countries.

ATC L01FX02

Checked against SÚKL (Czech Republic) on

Informational only — not a medical device.

SOURCE REGISTER · CZSÚKL (Czech Republic)normalisedMYLOTARGATCL01FX02REGISTER NO.CZ-0222910PACKS LISTED1CHECKEDSeptember 28, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about gemtuzumab ozogamicinAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Gemtuzumab ozogamicin is registered in 12 of 19 countries.

Countries holding a registration under ATC L01FX02 (gemtuzumab ozogamicin), each read from that country’s own register.

  • This record: Czechia, from SÚKL (Czech Republic)
  • 8 of them publish a price we can compare per daily dose
Search gemtuzumab ozogamicin products by name

Gemtuzumab ozogamicin · ATC L01FX02

12 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

SÚKL (Czech Republic)
Active substance
GEMTUZUMAB OZOGAMICIN
Manufacturer
Pfizer Europe MA EEIG, Bruxelles
Country
Czechia (CZ)
ATC code
L01FX02
ATC class
Gemtuzumab ozogamicin
Defined daily dose
2.1 mg, P
Reimbursed
Not published by this register
Source register
SÚKL (Czech Republic)
Last checked
September 28, 2026

Packs & prices · 1

1 priced
  • cz_kod_sukl
    0222910
    1
    CZK 203974.72

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

112 interactions on record for gemtuzumab ozogamicin.

Graded by severity as the source publishes them — 33 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check gemtuzumab ozogamicin against other medicinesHow interaction checks work

Gemtuzumab ozogamicin · interactions on record

112 records

  • 33 severe
  • 64 moderate
  • 15 minor

Most severe, free to view

  • MipomersenC10AX11severe
  • LomitapideC10AX12severe
  • CladribineL01BB04severe
  • PexidartinibL01EX15severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Gemtuzumab ozogamicin in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All gemtuzumab ozogamicin products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Mylotarg
  • Liechtenstein · Mylotarg
  • Norway · Mylotarg

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/e2ed4c79-cacb-4023-9e3d-cb3d6c03d129
GET /v1/drugs/e2ed4c79-cacb-4023-9e3d-cb3d6c03d129?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "INF PLV CSL",
  "source": "sukl",
  "strength": "5MG",
  "pack_size": "1",
  "substance": "GEMTUZUMAB OZOGAMICIN",
  "cz_kod_sukl": "0222910",
  "product_type": null,
  "substance_codes": "21151",
  "registration_state": "R",
  "registration_number": "EU/1/18/1277/001"
}
API referenceMCP serverPlans

See everything about gemtuzumab ozogamicin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console